LONDON (ShareCast) - Drug developer Ardana fell back on a disappointing trial result for its new testosterone cream, which is now unlikely to meet the expected target for patients to get approval from the US Food and Drug Administration.

"It would be prudent to assume that a further study may be required for regulatory approval of Testosterone Cream," Ardana said.

The company added that it continues to hold discussions with potential bidders and also over licensing opportunities.

Inkjet printing specialist Xaar said gross margins across the product range are stable, operating costs continue to be controlled successfully and trading for the company as a whole for 2008 is in line with expectations.

FTSE TechMARK - Fallers
Ardana (ARA) 13.00p -17.46%
NXT (NTX) 20.75p -7.78%
Skyepharma (SKP) 9.33p -6.70%
Phytopharm (PYM) 21.00p -5.62%
Optos (OPTS) 176.00p -4.61%
Detica Group (DCA) 297.00p -3.88%
Wolfson Microelectronics (WLF) 132.50p -3.81%
Parity Group (PTY) 31.00p -3.12%
Oxford Biomedica (OXB) 23.25p -3.12%
Antisoma (ASM) 27.00p -2.70%

FTSE TechMARK - Risers
Vectura Group (VEC) 53.50p +5.94%
KCOM Group (KCOM) 55.75p +5.69%
Pace Micro (PIC) 86.00p +3.61%
Vtech (VTH) 307.50p +3.36%
Biocompatibles International (BII) 151.75p +3.06%
Renovo Group (RNVO) 34.00p +3.03%
Intec Telecom (ITL) 54.25p +2.84%
Imagination Technologies (IMG) 73.75p +2.43%
Xaar (XAR) 185.50p +1.92%
GB Group (GBG) 30.75p +1.65%

• News Channel